Mer­ck gets a PDU­FA date for its chron­ic cough con­tender; Mor­phic shares sky­rock­et on the heels of PhI da­ta roll­out in IBD

Mer­ck should know be­fore the end of this year whether or not the FDA will ap­prove its drug gefapix­ant for chron­ic cough. The reg­u­la­tor has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.